ArticleBMC neurology2007
Brain type carnosinase in dementia: a pilot study.
Article in BMC neurology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Considerations for Carnosine Actions in Biology.Neurochemical research · 2026Review
- Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.medRxiv : the preprint server for health sciences · 2025Article
- Preclinical evidence and therapeutic perspectives on carnosine for the treatment of neurodegenerative disorders.AIMS neuroscience · 2025Review
- State of the Art in the Development of Human Serum Carnosinase Inhibitors.Molecules (Basel, Switzerland) · 2024Review
- Comprehensive pan-cancer investigation of carnosine dipeptidase 1 and its prospective prognostic significance in hepatocellular carcinoma.Open medicine (Warsaw, Poland) · 2024Article
- Antioxidant and Neuroprotective Effects of Carnosine: Therapeutic Implications in Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2022Review
- The Potential Use of Carnosine in Diabetes and Other Afflictions Reported in Long COVID Patients.Frontiers in neuroscience · 2022Review
- The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence.Nutrients · 2019Review
- Carnosinase, diabetes mellitus and the potential relevance of carnosinase deficiency.Journal of inherited metabolic disease · 2018Review
- Acute Carnosine Administration Increases Respiratory Chain Complexes and Citric Acid Cycle Enzyme Activities in Cerebral Cortex of Young Rats.Molecular neurobiology · 2016Article
- Article
- Carnosinases, their substrates and diseases.Molecules (Basel, Switzerland) · 2014Review
- Anti-aggregating effect of the naturally occurring dipeptide carnosine on aβ1-42 fibril formation.PloS one · 2013Article
- Article
- Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe pathological processes underlying dementia are poorly understood and so are the markers which identify them. Carnosinase is a dipeptidase found almost exclusively in brain and serum. Carnosinase and its substrate carnosine have been linked to neuropathophysiological processes.
methodsCarnosinase activity was measured by a flourometric method in 37 patients attending a Geriatric Outpatient Clinic. There were 17 patients without dementia, 13 had Alzheimer's disease (AD) and 7 had mixed dementia (MD).
resultsThe range of serum carnosinase activity for patients without dementia was 14.5 - 78.5 micromol/ml/h. There was no difference in carnosinase activity between patients without dementia (40.3 +/- 15.2 micromol/ml/h) and patients with AD (44.4 +/- 12.4 micromol/ml/h) or MD (26.6 +/- 15 micromol/ml/h). However, levels in the MD group were significantly lower than the AD group (p = 0.01). This difference remained significant after adjusting for gender, MMSE score, exercise, but not age, one at a time and all combined. The effect of other medical conditions did not remove the significance between the AD and MD groups. The MD group, but not the AD group, demonstrated a significant trend with carnosinase activity decreasing with duration of disease (from first recorded date of diagnosis to date of blood collection) (r = -0.76, p = 0.049). There was no association with carnosinase activity and MMSE score in the AD or MD group. Both AD and MD patients on any dementia medication (donepezil, galantamine, memantine) had higher carnosinase activity compared to those not taking a dementia medication. Carnosinase activity was higher in patients who regularly exercised (n = 20) compared to those who did not exercise regularly (n = 17)(p = 0.006).
conclusionThis exploratory study has shown altered activities of the enzyme carnosinase in patients with dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.